Wyeth

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.

Market Access Veteran Ellen Cappellino Joins Klick Health

Retrieved on: 
Thursday, October 26, 2023
Managed Care, General Health, Social Media, Professional Services, Search Engine Marketing, Digital Marketing, Public Relations, Investor Relations, Marketing, Advertising, Communications, Consulting, Health, AstraZeneca, Social media, Human, ChatGPT, Wyeth, News, MBA, Research, Albany College of Pharmacy and Health Sciences, Pfizer, Digital health, Caregiver, Type 2 diabetes, Click, Market access, Mayo Clinic Proceedings, Vertex Pharmaceuticals, AI, Patient, Bachelor of Science in Human Biology, Management, Pharmaceutical industry, Access, Giovanni Domenico Cappellino, New York University

Klick Health today announced that admired market access professional Ellen Cappellino has joined the agency to further build out its value, access, and reimbursement capabilities and help transform the healthcare experience for patients.

Key Points: 
  • Klick Health today announced that admired market access professional Ellen Cappellino has joined the agency to further build out its value, access, and reimbursement capabilities and help transform the healthcare experience for patients.
  • Klick Chief Medical Officer Holly Henry said Cappellino has the scientific background, clinical comprehension, and market access expertise they were looking for in a leader who can both develop the value story and generate maximum value for clients using health economics and outcomes research and real-world data.
  • Having worked within a variety of pharmaceutical organizations, Henry added that Cappellino is also a seasoned pro when it comes to approaching market access with a client-side perspective in mind.
  • “We are excited that Ellen has joined our growing Market Access team as we supercharge our Value, Access, and Reimbursement offering,” Henry said.

Actym Appoints Steven Vicik as Chief Technical Officer

Retrieved on: 
Thursday, October 26, 2023
Chemical engineering, CMC, Tufts University, Doctor of Philosophy, Wyeth, Control, Pfizer, New Drug Application, Tumor microenvironment, NDA, Therapy, TME, Genetics Institute, BLA, Pharmaceutical industry

BERKELEY, Calif., Oct. 26, 2023 /PRNewswire/ - Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik, PhD, as Chief Technical Officer (CTO).

Key Points: 
  • BERKELEY, Calif., Oct. 26, 2023 /PRNewswire/ - Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik, PhD, as Chief Technical Officer (CTO).
  • "Welcoming Steve to Actym represents a valuable addition to our expert-led management team," said Dr. Christopher D. Thanos, President, CEO, and Co-founder of Actym.
  • Commenting on his appointment, Dr. Vicik added, "Actym is developing an innovative drug modality with exciting potential to reprogram the TME.
  • Before joining Actym, Dr. Vicik served as CTO at Xalud Therapeutics, a clinical-stage biotechnology company that specializes in developing a non-viral gene therapy platform.

Andrew Wyeth Uncovered at American Fine Art, Inc

Retrieved on: 
Tuesday, October 17, 2023
Newton, American Fine Arts Society, Museum, Manhattan Project, Painting, American Scene, Memory, Imagination, Wyeth, Collection, Manhattan, History, Life, Photography, Interior design, Arts district

SCOTTSDALE, Ariz., Oct. 17, 2023 /PRNewswire/ -- Open to the public on November 9th, 2023, Andrew Wyeth: Uncovered features an intimate look into the life and surroundings of one of America's greatest painters through the lens of Newton O. Belt, a hobbyist photographer, artist, and neighbor of the Wyeth's. Mr. Belt was inspired to be an artist directly by Andrew Wyeth himself. The collection of black and white images dates from the 1950s and has never before been seen by the public. Over a hundred black and white negatives over seventy years old were carefully processed and printed, saving a piece of history. This rare opportunity allows the public to see photos of Wyeth's family including Jamie Wyeth and John W. McCoy, as well as photos of the surroundings of his home in Pennsylvania the subject of many of his renowned paintings.

Key Points: 
  • Mr. Belt was inspired to be an artist directly by Andrew Wyeth himself.
  • Now Andrew Wyeth is considered one of the most influential American painters, along with Jackson Pollock, Jasper Johns, Edward Hopper, Georgia O'Keeffe, Winslow Homer, and a few others.
  • In addition to the original works of Andrew Wyeth, American Fine Art specializes in the 19th-21st century masters including Picasso, Chagall, Miro, Warhol, Dali, Leger, Banksy, and more.
  • American Fine Art is an international leader in fine art and Scottsdale's premier fine art gallery.

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

Retrieved on: 
Monday, October 16, 2023
Kutztown University of Pennsylvania, Drug development, Vaccine, Biology, Genzyme, Organization, Therapy, Reata Pharmaceuticals, Biotechnology, AbbVie, Emerging market, Diabetes, Wyeth, AstraZeneca, Chemistry, Rare, SAN, Temple University, Patient, Regulatory affairs, Pharmaceutical industry, Quality, Sanofi

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer.
  • “Mishima brings a dynamic set of drug development experiences including the design and execution of global regulatory strategies in support of preclinical to commercial-stage programs,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer at Pliant.
  • Ms. Gerhart previously held the role of Chief Regulatory Officer and Head of Quality at Taysha Gene Therapies where she established and grew the regulatory and quality organizations and was responsible for all US and Ex-US regulatory interactions.
  • Prior to this, Ms. Gerhart was Head of Regulatory at Genzyme and held regulatory positions of increasing seniority at AbbVie, Reata Pharmaceuticals, Pfizer/ Wyeth, AstraZeneca, and Wyeth.

Future Fields Announces New Paradigm in CDMO Services Optimized for Small-to-Medium-Sized Biopharma Companies

Retrieved on: 
Wednesday, September 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Other Health, GSK plc, Therapy, Fruit, Carbon, Doctor of Philosophy, Advisory board, Bioreactor, Organization, Protein, CDMO, Traction, Drug discovery, Biocon, Wyeth, A-DNA, Fine chemical, Genzyme, Pfizer

“Small and mid-sized biopharma companies are already looking to Future Fields for flexible, lower-cost custom protein services that are eco-friendly and capable of bringing therapeutics to market faster, and we are pleased to make this offering more broadly available,” said Matt Anderson-Baron, PhD, co-founder and CEO of Future Fields.

Key Points: 
  • “Small and mid-sized biopharma companies are already looking to Future Fields for flexible, lower-cost custom protein services that are eco-friendly and capable of bringing therapeutics to market faster, and we are pleased to make this offering more broadly available,” said Matt Anderson-Baron, PhD, co-founder and CEO of Future Fields.
  • Future Fields strives to help the biopharmaceutical industry reduce the carbon impact caused by traditional bioreactors and enhance sustainability.
  • Mr. Hart has worked with large biopharma companies, such as Amgen, Shire, Genzyme, GlaxoSmithKline, and Wyeth, and he has led small-and-medium-sized biopharma companies.
  • “Now, companies at every stage of development can access CDMO services that enable them to accelerate the development of their protein-based therapeutics.”

Character Biosciences Strengthens Leadership Team with Appointment of Laura Carter, Ph.D. as Chief Scientific Officer

Retrieved on: 
Wednesday, September 13, 2023
Health, Genetics, Radiology, Pharmaceutical, Optical, Biotechnology, Character, University, Therapy, Clinical trial, Cancer, MedImmune, Coronavirus Scientific Advisory Board, Research, History, HIV disease progression rates, Autoimmune disease, Medicine, Drug discovery, Entrepreneurship, Bank, Wyeth, Massachusetts Institute of Technology, Disease, Medical device

Character Biosciences, a drug discovery and development company leveraging human genetics and medical imaging-based machine learning to target disease progression, today announced the appointment of Laura Carter, Ph.D. as Chief Scientific Officer.

Key Points: 
  • Character Biosciences, a drug discovery and development company leveraging human genetics and medical imaging-based machine learning to target disease progression, today announced the appointment of Laura Carter, Ph.D. as Chief Scientific Officer.
  • Dr. Carter brings a track record of more than 20 years of scientific leadership and expertise to Character, spanning target ID/validation through late stage clinical development across multiple therapeutic areas.
  • “We are thrilled to welcome Laura to the Character team, and to tap into her strategic vision and strong history of developing innovative therapeutics,” said Cheng Zhang, Co-Founder and Chief Executive Officer of Character Biosciences.
  • Dr. Carter received her Ph.D. from the University of California San Diego School of Medicine and her S.B.

Global Medical Tubing Market Analysis Report 2023-2030: Manufacturers Seeking Collaborations to Help Spur Innovative Solutions - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Health, Medical Supplies, Medical Devices, Infection, Tissue, Insurance, Silicone, Asthma, TPE, Prevalence, Diabetes, Wyeth, Arthritis, Administration, Estradiol acetate, Freudenberg, Cancer, Lung cancer, Needle, Nordson Corporation, Instrument, Noetics, USD, NDC, Pulmonary fibrosis, Silicon, Back pain, Acquisition, Medicaid, Warner Chilcott, Conditional sentence, Growth, WHO, Chronic obstructive pulmonary disease, NHE, Ministry, World Health Organization, Syringe, Dietary supplement, Pharmaceutical industry, Levonorgestrel-releasing implant

The "Medical Tubing Market Size, Share & Trends Analysis Report By Product Type (Silicone, Polyolefins, Polyimide), By Application (Bulk Disposable Tubing), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Tubing Market Size, Share & Trends Analysis Report By Product Type (Silicone, Polyolefins, Polyimide), By Application (Bulk Disposable Tubing), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global medical tubing market size is anticipated to reach USD 19,498.5 million by 2030.
  • These factors are anticipated to fuel the growth of medical tubing product demand over the forecast period.
  • Medical tubing manufacturers are seeking collaborations, mergers, and acquisitions to develop advanced and innovative solutions.

NeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA as Chief Business Officer

Retrieved on: 
Monday, July 31, 2023
Central nervous system, NTS, University, Doctor of Philosophy, Stroke, MBA, Research, Biology, CNS, Rutgers University, Traumatic brain injury, Wyeth, Therapy, Summit, Injury, Endo International, Management, Neuroscience

ATLANTA, July 31, 2023 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries, including stroke and traumatic brain injury, today announced the appointment of Kevin Pong, PhD, MBA as Chief Business Officer. In this position, Dr. Pong is responsible for the strategic leadership of the company's global business development, licensing, and alliance management activities.

Key Points: 
  • ATLANTA, July 31, 2023 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries, including stroke and traumatic brain injury, today announced the appointment of Kevin Pong, PhD, MBA as Chief Business Officer.
  • In this position, Dr. Pong is responsible for the strategic leadership of the company's global business development, licensing, and alliance management activities.
  • "We are delighted to welcome Kevin to our executive leadership team," said Carl Long, Chief Executive Officer.
  • Most recently, he served as Chief Business Officer of Anima Biotech, where he drove multiple transformative transactions and helped evolve the company's partnering strategy.